Amgen (NASDAQ: AMGN) announced that CVS Health (NYSE:CVS) will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial formularies. "Ensuring access to Repatha for ...
Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...
Amgen on Friday revealed its PCSK9 drug Repatha (evolocumab) reduced the risk of major adverse cardiovascular events but had no effect on cardiovascular death, mixed results which could spell ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...
Amgen still hopes new cardiovascular data will solve a problem facing cholesterol drug, Repatha – in almost eight out of ten cases US insurers and Medicare initially refuse to prescribe the drug. One ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback